← Back to patent-cliff list
Eclitasertib
Tier C — Watch / tradeEclitasertib
Sanofi
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：RIPK1
Indications (approved)：Ulcerative colitis, Cutaneous lupus erythematosus, 冠状病毒感染
Regional status
US
Phase II
2021-04-01
EU
Phase II
2021-04-01
China
Phase II
2022-11-25
Japan
Phase II
2022-11-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Eclitasertib?
Approved indications include: Ulcerative colitis, Cutaneous lupus erythematosus, 冠状病毒感染.
When does the Eclitasertib patent expire?
No public expiry year is available for Eclitasertib yet; this page updates once verified.
How do I get a quote for Eclitasertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21